Hendriksz Christian J, Berger Kenneth I, Giugliani Roberto, Harmatz Paul, Kampmann Christoph, Mackenzie William G, Raiman Julian, Villarreal Martha Solano, Savarirayan Ravi
Salford Royal NHS Foundation Trust, Salford, UK.
Am J Med Genet A. 2015 Jan;167A(1):11-25. doi: 10.1002/ajmg.a.36833. Epub 2014 Oct 24.
Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems. The clinical presentation, onset, severity and progression rate of clinical manifestations of Morquio A syndrome vary widely between patients. Because of the heterogeneous and progressive nature of the disease, the management of patients with Morquio A syndrome is challenging and requires a multidisciplinary approach, involving an array of specialists. The current paper presents international guidelines for the evaluation, treatment and symptom-based management of Morquio A syndrome. These guidelines were developed during two expert meetings by an international panel of specialists in pediatrics, genetics, orthopedics, pulmonology, cardiology, and anesthesia with extensive experience in managing Morquio A syndrome.
莫尔基奥A综合征(黏多糖贮积症IVA型)是一种溶酶体贮积病,与骨骼和关节异常以及包括呼吸系统疾病、脊髓受压、心脏病、视力受损、听力丧失和牙齿问题在内的严重非骨骼表现相关。莫尔基奥A综合征的临床表现、发病情况、严重程度和临床表现进展速度在患者之间差异很大。由于该疾病具有异质性和进行性,对莫尔基奥A综合征患者的管理具有挑战性,需要多学科方法,涉及一系列专家。本文介绍了莫尔基奥A综合征评估、治疗和基于症状管理的国际指南。这些指南是在两次专家会议期间由国际儿科、遗传学、骨科、肺病学、心脏病学和麻醉学专家小组制定的,他们在管理莫尔基奥A综合征方面拥有丰富经验。